Lemmer B, Langer L, Ohm T, Bohl J
Zentrum der Pharmakologie, J.W. Goethe-Universität Frankfurt, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 1993 Feb;347(2):214-9. doi: 10.1007/BF00169270.
beta-Adrenoceptor density and beta 1- and beta 2-subtype distribution were examined in hippocampi and cerebella from patients with Alzheimer's disease (AD/SDAT). Tissues from age-, sex and post-mortem delay matched non-demented patients served as controls. The total beta-adrenoceptor density as evaluated in saturation experiments with the hydrophilic radioligand [3H]CGP 12177 was higher in hippocampal (36-39 fmol/mg protein) than cerebellar tissues (20-21 fmol/mg), however, no differences were found in either brain region between AD/SDAT patients and controls. Subtype distribution using the highly selective beta 1-adrenoceptor antagonist CGP 20712A revealed a slightly higher proportion of beta 1-adrenoceptors in hippocampus (26%-27%) than in cerebellum (20%-21%) with, again, no difference between AD/SDAT and controls. We recently described a 40% reduction in basal and stimulated adenylyl cyclase activity in post-mortem hippocampus of AD/SDAT patients, a brain region greatly affected by the disease, the present data now demonstrate that this disease-related effect is not mirrored by a similar change in beta-adrenoceptor density nor in subtype distribution.
对阿尔茨海默病（AD/SDAT）患者的海马体和小脑进行了β-肾上腺素能受体密度以及β1和β2亚型分布的检测。选取年龄、性别和死后延迟时间相匹配的非痴呆患者的组织作为对照。在用亲水性放射性配体[3H]CGP 12177进行的饱和实验中评估的总β-肾上腺素能受体密度，海马体组织（36 - 39 fmol/mg蛋白质）高于小脑组织（20 - 21 fmol/mg），然而，AD/SDAT患者与对照组在这两个脑区均未发现差异。使用高选择性β1-肾上腺素能受体拮抗剂CGP 20712A进行的亚型分布研究显示，海马体中β1-肾上腺素能受体的比例（26% - 27%）略高于小脑（20% - 21%），同样，AD/SDAT患者与对照组之间也没有差异。我们最近描述了AD/SDAT患者死后海马体中基础和刺激状态下的腺苷酸环化酶活性降低40%，海马体是受该疾病严重影响的脑区，目前的数据表明，这种与疾病相关的效应并未反映在β-肾上腺素能受体密度或亚型分布的类似变化中。
